Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Any comments from the experts on this release?

QIAGEN Acquires the SAWADY Group in Japan Accretive Acquisition
Accelerates Penetration of QIAGEN's Synthetic Nucleic Acid Business in the
Second Largest Life Science Market in the World

VENLO, Netherlands and TOKYO, April 24 /PRNewswire Interactive News Release/
-- QIAGEN, N.V. (Nasdaq: QGENF, Neuer Markt: QIA, Easdaq: QGEN) today announced
the acquisition of the SAWADY Group of companies ("SAWADY Group"). QIAGEN
believes that the SAWADY Group has built a very strong reputation and position
as the second largest suppliers of synthetic nucleic acids in Japan.

Located in Tokyo, Japan, the SAWADY Group employs over 40 people and for the
year 2000 recorded net sales of approximately US$10.0 million and net income of
$0.9 million.

Under the terms of the agreement QIAGEN issued 854,987 shares of its common
stock, valued at the time of the closing at approximately $18 million, in
exchange for all of the outstanding capital stock of SAWADY Technology Co.,
Ltd., Omgen Co., Ltd. and a majority position in Accord Co., Ltd., the three
companies comprising SAWADY Group. The SAWADY Group was managed and structured
as one organization, but was organized as three companies to meet the tax
planning and other preferences of its shareholders. The transaction is intended
to qualify as a tax-free reorganization and will be accounted for as a pooling
of interests. QIAGEN expects to incur charges relating to the acquisition of
approximately $3.0 million net after taxes. The closing of the transaction
occurred on March 31, 2001. Excluding the effect of these charges (approximately
$0.02 per share), QIAGEN expects this transaction to have an immediate positive
impact on QIAGEN's net income per share.

In June 2000, QIAGEN acquired Operon Technologies (Operon), which is believed to
be the leader in the market for synthetic nucleic acids (oligonucleotides,
synthetic genes and related products) in the United States. QIAGEN is currently
opening manufacturing facilities in Europe applying Operon's manufacturing
technologies. QIAGEN believes that the acquisition of SAWADY Group greatly
accelerates QIAGEN's penetration of the Japanese market, which is believed to be
the second largest market in the world. QIAGEN intends to leverage Operon's
technology-leading position in synthetic nucleic acids with the strong market
position which the SAWADY Group has created in Japan to address this rapidly
expanding market. QIAGEN believes that the worldwide market for synthetic
nucleic acid products in 2000 was approximately US$200 million and is growing
rapidly. The contribution of revenues from synthetic nucleic acid products
represented approximately 10% of QIAGEN's year 2000 revenues which amounted to
over US$204 million.

"This is a great opportunity for QIAGEN. We believe that QIAGEN can greatly
accelerate the creation of a leading position in Japan for our synthetic nucleic
acid products with which we have already created a market and technology-leading
position in the United States," said Dr. Metin Colpan, QIAGEN's Chief Executive
Officer. "QIAGEN already has a strong presence in Japan. Our Japanese
subsidiary, which we opened in 1998 for the full range of our products, built
this market into one of the largest for QIAGEN, second only to the revenue
contribution we generate in the United States."

"We are excited to join forces with QIAGEN -- the market and technology leader
for products for nucleic acid handling, separation and purification," said
Masanori Masuo, SAWADY's President. "Our products allow a very synergistic fit
with QIAGEN's product offerings. Together, we believe that we can provide a
product portfolio that offers a significant benefit for QIAGEN's and SAWADY's
customers. We believe that by joining forces with QIAGEN and their Operon
Technologies units we can greatly accelerate our presence as a leading supplier
to the rapidly growing genomics markets in Japan."


QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the
United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia
and Canada, believes it is the world's leading provider of innovative enabling
technologies and products for the separation, purification and handling of
nucleic acids. The Company has developed a comprehensive portfolio of more than
320 proprietary, consumable products for nucleic acid separation, purification
and handling, nucleic acid amplification, as well as automated instrumentation,
synthetic nucleic acid products and related services. QIAGEN's products are sold
in more than 42 countries throughout the world to academic research markets and
to leading pharmaceutical and biotechnology companies. In addition, the Company
is positioning its products for sale into developing commercial markets,
including DNA sequencing and genomics, nucleic acid-based molecular diagnostics,
and genetic vaccination and gene therapy. QIAGEN employs approximately 1,400
people worldwide. Further information on QIAGEN can be found at


SAWADY was established in May 1993 and is a leading supplier of synthetic
nucleic acid products and genomics services to customers in the Japanese life
sciences market. The company is committed to supplying high-quality products at
competitive prices. Demand for custom, synthetic DNA products is increasing
rapidly in Japan, due to the rapid growth in research areas such as gene chips
and SNP analysis. The state-of-the-art facilities at SAWADY include nucleic acid
synthesis and oligonucleotide purification systems built around proprietary
technologies developed at SAWADY. Further information on SAWADY can be found at
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.